T Cell

Adoptive T cell therapy is a type of immunotherapy with the ability to target cancer cells through inherent mechanisms of the immune system. The method works by infusing tumor-specific cytotoxic T cells into patients which will recognize, target and attack tumor cells.

Latest T Cell News and Research

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Solove Research Institute (OSUCCC - James) has identified a protein within certain immune cells that is required for optimal immune responses to cancer.

Toshiba Corporation and a team led by Professor Yozo Nakazawa at the Department of Pediatrics, Shinshu University, have together developed a “tumor-tropic liposome technology” for gene therapy. The technology uses unique, nano-sized biodegradable liposomes developed by Toshiba to accurately and efficiently deliver therapeutic genes to targeted cancer cells, and achieves safer gene delivery than viruses used as carriers.

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

Scientists across the globe are racing to develop a vaccine that can provide protection against coronavirus disease (COVID-19). An effective and safe vaccine would curb not only the current coronavirus pandemic but also prevent future outbreaks

The global COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading over the world. However, not much is known about how the adaptive immune response kicks in following the viral challenge. This knowledge is crucial to predicting the efficacy of a vaccine and estimating the chances of reinfection.

The first COVID-19 vaccine to reach phase 1 clinical trial has been found to be safe, well-tolerated, and able to generate an immune response against SARS-CoV-2 in humans, according to new research published in The Lancet.

With many hundreds of thousands of deaths due to the current COVID-19 pandemic, there is a rush to find an effective vaccine or drug against the virus. A new study on the preprint server medRxiv* in May 2020 shows that the use of some biologically plausible drugs may be counterproductive, and care should be taken when trying out unproven therapies.

By employing an immunoinformatics approach, a new study available on the preprint server bioRxiv* shows how the combination of peptides designed from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid phosphoprotein and spike glycoprotein may trigger an improved immunological response with respectable safety profile, informing, in turn, further vaccine development.

From testing drugs to developing vaccines, the close study of the immune system is key to improving real-world health outcomes. T-cells are integral to this research, as these white blood cells help tailor the body's immune response to specific pathogens.

For years, surgeons have operated on pancreatic cancer patients to remove what they thought was a localized tumor only to discover that the disease had spread to other, inoperable parts of the body. Now, a City of Hope molecular scientist thinks he may have found a way to prevent ineffective surgeries and prolong the lives of these patients.

Boehringer Ingelheim today announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies targeting the tumor microenvironment, Boehringer Ingelheim is now positioned at the forefront of the stromal biology space - an emerging area in cancer immunology.

Takeda Pharmaceutical Company Limited today announced that the company will present data from its expanding oncology pipeline and established product portfolio at two upcoming virtual scientific congresses: the 56th Annual Meeting of the American Society of Clinical Oncology, May 29-31 and the 25th Virtual Congress of the European Hematology Association, June 11-14.

Although scientists and stock markets have celebrated the approval for emergency use of remdesivir to treat COVID-19, a cure for the disease that has killed nearly 260,000 people remains a long way off — and might never arrive.

Some people with HIV need to undergo an allogeneic stem cell transplantation in order to treat different types of blood cancer. Most of the patient's immune cells are eliminated during these transplantations.

A new study by researchers at the New York University Grossman School of Medicine and published on the preprint server medRxiv* in May 2020 reports that being infected with HIV at the time of acquiring COVID-19 does not significantly increase the severity of illness or the risk of complications.

Aiming to identify new therapeutic strategies for the aggressive hematological disease T-cell acute lymphoblastic leukemia (T-ALL), Rutgers Cancer Institute of New Jersey resident researcher Daniel Herranz Benito, PhD, along with collaborators from Princeton University, found a new drug that has therapeutic effect against T-ALL by inhibiting SHMT and is complementary to standard-of-care treatment.

Other Useful Links

News-Medical.Net provides this medical information service in accordance
with these terms and conditions.
Please note that medical information found
on this website is designed to support, not to replace the relationship
between patient and physician/doctor and the medical advice they may provide.